Gilead Sciences’ chronic hepatitis B treatment Vemlidy with health insurance benefits

Published: 2017-11-03 16:26:00
Updated: 2017-11-03 15:36:59

Vemlidy(generic name: Tenofovir Alafenamide Fumarate), a Gilead Sciences Korea’s(CEO Seung-Woo Lee) chronic hepatitis B treatment, will receive the national health insurance benefits from the 1st of November.

Vemlidy, a tenofovir prodrug, was approved from the Ministry of Food and Drug Safety on...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.